J 2023

Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

ILARIA, Del Principe Maria, Danila SEIDEL, Marianna CRISCUOLO, Michelina DARGENIO, Zdeněk RÁČIL et. al.

Basic information

Original name

Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

Authors

ILARIA, Del Principe Maria (guarantor), Danila SEIDEL, Marianna CRISCUOLO, Michelina DARGENIO, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Monica PIEDIMONTE, Francesco MARCHESI, Gianpaolo NADALI, Philipp KOEHLER, Nicola FRACCHIOLLA, Chiara CATTANEO, Nikolai KLIMKO, Angelica SPOLZINO, Deniz Yilmaz KARAPINAR, Hayati DEMIRASLAN, Rafael F DUARTE, Judit DEMETER, Marta STANZANI, Lorella Maria Antonia MELILLO, Claudia Maria BASILICO, Simone CESARO, Giovangiacinto PATERNO, Catello CALIFANO, Mario DELIA, Elisa BUZZATTI, Alessandro BUSCA, Oliver A CORNELY, Livio PAGANO, Nael ALAKEL, Valentina Arsi ARSENIJEVI'C, Vincent CAMUS, Iker FALCES-ROMERO, Levy ITZHAK, Michal KOUBA (203 Czech Republic), Rodrigo MARTINO, Petr SEDLACEK (203 Czech Republic) and Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution)

Edition

Mycoses, Hoboken, Wiley-Blackwell, 2023, 0933-7407

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.900 in 2022

RIV identification code

RIV/00216224:14110/23:00130241

Organization unit

Faculty of Medicine

UT WoS

000855011600001

Keywords in English

antifungal treatment; Candidemia; fungal infection; Geotrichum; Magnusiomyces; Saprochaete

Tags

International impact, Reviewed
Změněno: 4/10/2024 08:54, Mgr. Tereza Miškechová

Abstract

V originále

Background Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2-78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p < .0001). First-line antifungal therapy with azoles, alone or in combination, was associated with improved response compared to other antifungals (p = .001). Overall day-30 mortality rate was 43%. Factors associated with higher mortality rates were septic shock (HR 2.696, 95% CI 1.396-5.204, p = .003), corticosteroid treatment longer than 14 days (HR 2.245, 95% CI 1.151-4.376, p = .018) and lack of neutrophil recovery (HR 3.997, 95% CI 2.102-7.601, p < .001). The latter was independently associated with poor outcome (HR 2.495, 95% CI 1.192-5.222, p = .015). Conclusions Magnusiomyces-associated infections are often breakthrough infections. Effective treatment regimens of these infections remain to be determined, but neutrophil recovery appears to play an important role in the favourable outcome.